Developer docs
API playgroundTry for free, no card

Search company profiles

BigHat Biosciences

Full company profile

uuid00005r4

Namestring
BigHat Biosciences
Legal namestring
BigHat Biosciences, Inc.
Websiteurl
bighatbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

BigHat Biosciences is a Series B biotechnology company founded in 2019 and headquartered in San Mateo, California, that builds an AI/ML-guided antibody discovery and engineering platform called Milliner. Milliner integrates a synthetic-biology-based high-speed wet lab (cell-free protein synthesis, or CFPS) with proprietary pre-trained machine learning models in a weekly design-build-test-learn cycle, producing, purifying, and fully characterizing hundreds of recombinant antibodies per workcell across biophysical and functional assays including affinity, stability, solubility, specificity, and cell-based function. A custom-built cloud-native LIMS++ called Reccy orchestrates the instruments, robots, schedules, and data flows, holds SOC 2 Type 2 certification, and feeds a new AI orchestration layer called RADS (Reccy Antibody Design Studio) that runs a weekly competitive zoo of ML models on the freshest data, selects the best performer, and uses it to design the next week's antibody variants.

The company's business model rests on multi-year strategic collaborations with large biopharma (Eli Lilly, Johnson & Johnson, AbbVie, Amgen, Merck), each typically structured as upfront cash plus R&D funding, success-based milestone payments, and downstream economics on partnered programs. BigHat also retains a wholly-owned pipeline — most notably the next-generation ADC BHB810 for gastrointestinal cancers (paired with Synaffix/Lonza GlycoConnect, HydraSpace, and toxSYN technologies) and an expanding portfolio of T cell engagers including a first-in-class NOT-gated logic-gated design — with multiple programs on track to enter the clinic in 2026. Distribution is relationship-driven via direct enterprise sales to pharma partners, supplemented by technology ecosystem visibility through AWS Life Sciences Agents and thought leadership in peer-reviewed ML venues (ICLR, NeurIPS, PMLR).

BigHat has raised more than $140 million cumulatively from leading investors including Section 32, Andreessen Horowitz (a16z), 8VC, Amgen Ventures, Bristol Myers Squibb, and Eli Lilly (via corporate equity under Lilly Catalyze360 in April 2025). Leadership was upgraded in 2025-2026 with co-founder Peyton Greenside moving from CSO to CEO and the appointment of Stefan Weigand (former Head of Large Molecule Research at Roche, overseeing roughly 350 scientists and 60-plus molecules into clinic) as Chief Scientific Officer, formalizing the company's transition from a platform/collaboration business to a clinical-stage biotech.

Short descriptiontext

BigHat Biosciences is an AI/ML-guided antibody discovery and engineering company that uses a Milliner platform pairing cell-free synthetic biology with proprietary machine learning to design safer, more effective antibody therapeutics, partnering with leading biopharma (Lilly, J&J, AbbVie, Amgen, Merck) while advancing a wholly-owned pipeline of ADCs and T cell engagers toward the clinic in 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI antibody design, ML-guided biologics, protein therapeutics platform, synthetic biology discovery, antibody engineering services
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Driven Antibody Discovery & Engineering Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic biopharma collaborations
TypeProfessional Services
Description

Multi-program discovery and engineering partnerships with leading biopharma (Eli Lilly, J&J, AbbVie, Amgen, Merck). These typically include upfront cash, R&D funding, success-based milestone payments, and downstream economics tied to development and commercialization.

bighatbio.com
2Equity investments from pharma partners
TypeLicensing Royalties
Description

Strategic partners take equity stakes in BigHat alongside collaboration agreements (e.g., Eli Lilly equity investment under Lilly Catalyze360™ in April 2025). Equity capital supplements R&D funding and aligns partner incentives.

bighatbio.com
3Technology licensing (ADC platform inbound)
TypeLicensing Royalties
Description

Licenses inbound enabling technologies for internal programs — e.g., Synaffix (a Lonza company) GlycoConnect™, HydraSpace® and toxSYN® ADC technologies licensed for BigHat's next-gen ADC program, with associated development and manufacturing services from Lonza. BigHat retains full global rights to its programs.

genengnews.com
4Data and platform service arrangements
TypeProfessional Services
Description

BigHat contributes best-in-class ML expertise and high-quality Milliner-generated datasets to support external AI-enabled drug discovery platforms (e.g., Lilly TuneLab), enabling model benchmarking and foundation model training in exchange for collaboration value.

bighatbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based partnership pricing (not publicly disclosed)
ModelOther
Notes

Custom-negotiated enterprise partnerships with biopharma; no public price list. Two collaboration archetypes offered: Strategic Collaborations and High-Quality Antibodies Partnerships. Terms include upfront, milestones, and downstream economics; partner retains or shares program rights based on structure.

bighatbio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Milliner
Description

BigHat's AI/ML-powered, high-throughput, automated wet-lab antibody design and engineering platform; central data-generation engine that integrates synthetic biology with machine learning.

bighatbio.com
+2 more records
Core offering1 text field

BigHat Biosciences develops and operates the Milliner platform, a full-stack antibody discovery and engineering system that integrates a synthetic-biology-based high-speed wet lab (cell-free protein synthesis) with proprietary machine learning models in an iterative weekly design-build-test-learn cycle. The platform is commercialized through multi-program strategic collaborations with large biopharma (Eli Lilly, J&J, AbbVie, Amgen, Merck), supports BigHat's wholly-owned therapeutic pipeline (ADCs and T cell engagers in oncology and immunology), and is paired with technology licensing arrangements and platform service agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Hundreds of recombinant antibodies synthesized, purified, and characterized in a single weekly workcell
+6 more records
Product overview1 text field

BigHat Biosciences operates a single integrated platform architecture rather than a portfolio of disconnected products. The core platform, Milliner, pairs a synthetic-biology-based high-throughput wet lab with machine-learning-guided design in a weekly design-build-test cycle. Sitting on top of Milliner is Reccy Antibody Design Studio (RADS), the AI orchestration layer that trains a weekly "zoo" of models and selects the best to design the next batch of antibodies, while Reccy itself (BigHat's custom LIMS++) acts as the data-control plane connecting instruments, robots, schedulers, and ML pipelines. These platform capabilities power BigHat's internal pipeline of wholly-owned therapeutics (BHB810 ADC for GI cancers, BHB299 and the avidity, AND-gated, and NOT-gated TCE programs in oncology and I&I), alongside partner programs with AbbVie, Johnson & Johnson, Amgen, Merck, Eli Lilly, and Lonza/Synaffix.

Product and service1 record
1Milliner Platform
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Collaboration to advance machine learning-enabled biologics discovery through Lilly TuneLab. BigHat will leverage its ML expertise and Milliner platform to rapidly generate diverse, high-quality datasets suitable for use in a generalizable antibody developability foundation model. Expands BigHat's existing relationship with Lilly.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-26
Description

BigHat uses AWS to build digitally connected labs and is featured among customers in AWS's agentic AI life sciences portfolio announcement, alongside Bayer AG, Natera, Foundation Medicine, and Resilience. AWS previewed BigHat-related demonstrations at re:Invent 2025.

3Johnson & Johnson (Janssen Biotech, Inc.)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

Strategic collaboration to leverage BigHat's integrated machine learning platform to design novel and challenging antibodies, successfully completed. Next stage advances multiple novel sequences targeting neuroscience therapeutic area.

bighatbio.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-04-17
Description

Strategic collaboration to co-develop up to two antibody therapeutic programs using BigHat's Milliner platform. Lilly Catalyze360™ provides support while BigHat retains full global rights to its GI cancer ADC program. Includes equity investment from Lilly.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-10-30
Description

Commercial license of Synaffix's late-clinical stage, site-specific ADC technology platform (GlycoConnect™, HydraSpace® and toxSYN® linker-payloads) for BigHat's next-gen ADC pipeline program. Through Lonza's umbrella, BigHat also gains access to end-to-end ADC development and manufacturing services (DNA-to-IND). The collaboration is critical for advancing BigHat's next-generation ADC program, currently at IND-enabling stage and on track to become BigHat's first clinical-stage program.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Research collaboration to leverage AI/ML to discover next-generation therapeutic antibodies. AbbVie cites the collaboration as evidence of its commitment to integrate AI/ML-based approaches in drug discovery and development. Third-party reporting indicates $30M upfront and up to $325M+ in milestones.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-phase research collaboration; completion of first stage demonstrated Milliner's ability to quickly and significantly optimize next-generation single-domain antibodies, validating the platform against traditional technologies. Philip Tagari (former VP of Research at Amgen) provided quote endorsing the collaboration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration applying AI/ML across Merck's drug discovery capabilities. Merck's Juan Alvarez (VP of Discovery Biologics) cites the agreement as expanding their AI/ML strategy to enable molecular design of novel biologic candidates.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Flagship-backed AI-driven generative biology company developing de novo protein therapeutics, including antibodies, using foundation models and a wet-lab learning loop. Most direct competitor to BigHat's ML-guided antibody discovery and engineering model.

TypeDirect peer
Description

ML-driven drug discovery company combining high-throughput biology, induced pluripotent stem cell-derived disease models, and ML to discover and develop therapeutics, including biologics. Overlaps with BigHat on the wet-lab-plus-ML platform thesis and biopharma partnership model.

TypeEmerging player
Description

Flagship-backed gene writing company combining ML-driven protein engineering with synthetic biology. Shares BigHat's integration of ML and synthetic biology, though focused on genome engineering rather than antibody therapeutics.

TypeEmerging player
Description

Amsterdam-based AI company applying generative ML to protein engineering across modalities, with a partnership-led business model. Comparable in applying foundation models and ML to protein design, though its primary focus is broader than antibodies.

TypeEmerging player
Description

London-based AI-driven antibody discovery company using a closed-loop design-build-test-learn cycle to engineer next-generation antibody therapeutics. Closely mirrors BigHat's automation-plus-ML approach in the antibody niche, with a more recent funding history.

TypeDirect peer
Description

Public antibody discovery company combining high-throughput single-cell screening with computational/ML approaches to discover and optimize antibody therapeutics, with a similar partnership-driven business model serving top biopharma.

7Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed drug discovery company spun out of DeepMind applying AlphaFold-derived AI to therapeutics design, including biologics. Direct competitor in the AI/ML-driven protein and antibody design space with substantially greater capital and compute resources.

TypeBroad incumbent
Description

Public techbio company combining high-throughput automated wet-lab experimentation with ML at scale, focused on small molecule and target identification. Adjacent platform model with overlap in ML-guided biology and biopharma partnerships, though concentrated in small molecules rather than antibodies.

TypeBroad incumbent
Description

Public synthetic biology platform company combining automated high-throughput biology with ML for cell engineering and protein production. Overlaps with BigHat on the synthetic-biology-plus-ML platform concept, though Ginkgo's primary focus is organism engineering and biomanufacturing rather than antibody therapeutics.

TypeEmerging player
Description

Early-stage protein engineering company using high-throughput wet-lab experimentation and ML to accelerate protein design. Smaller and earlier-stage than BigHat, but operates in a similar ML-guided biologics design space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BigHat Biosciences

AI-Driven Antibody Discovery & Engineering Platformbighatbio.com

BigHat Biosciences is an AI/ML-guided antibody discovery and engineering company that uses a Milliner platform pairing cell-free synthetic biology with proprietary machine learning to design safer, more effective antibody therapeutics, partnering with leading biopharma (Lilly, J&J, AbbVie, Amgen, Merck) while advancing a wholly-owned pipeline of ADCs and T cell engagers toward the clinic in 2026.

What BigHat Biosciences does

BigHat Biosciences is a Series B biotechnology company founded in 2019 and headquartered in San Mateo, California, that builds an AI/ML-guided antibody discovery and engineering platform called Milliner. Milliner integrates a synthetic-biology-based high-speed wet lab (cell-free protein synthesis, or CFPS) with proprietary pre-trained machine learning models in a weekly design-build-test-learn cycle, producing, purifying, and fully characterizing hundreds of recombinant antibodies per workcell across biophysical and functional assays including affinity, stability, solubility, specificity, and cell-based function. A custom-built cloud-native LIMS++ called Reccy orchestrates the instruments, robots, schedules, and data flows, holds SOC 2 Type 2 certification, and feeds a new AI orchestration layer called RADS (Reccy Antibody Design Studio) that runs a weekly competitive zoo of ML models on the freshest data, selects the best performer, and uses it to design the next week's antibody variants.

The company's business model rests on multi-year strategic collaborations with large biopharma (Eli Lilly, Johnson & Johnson, AbbVie, Amgen, Merck), each typically structured as upfront cash plus R&D funding, success-based milestone payments, and downstream economics on partnered programs. BigHat also retains a wholly-owned pipeline — most notably the next-generation ADC BHB810 for gastrointestinal cancers (paired with Synaffix/Lonza GlycoConnect, HydraSpace, and toxSYN technologies) and an expanding portfolio of T cell engagers including a first-in-class NOT-gated logic-gated design — with multiple programs on track to enter the clinic in 2026. Distribution is relationship-driven via direct enterprise sales to pharma partners, supplemented by technology ecosystem visibility through AWS Life Sciences Agents and thought leadership in peer-reviewed ML venues (ICLR, NeurIPS, PMLR).

BigHat has raised more than $140 million cumulatively from leading investors including Section 32, Andreessen Horowitz (a16z), 8VC, Amgen Ventures, Bristol Myers Squibb, and Eli Lilly (via corporate equity under Lilly Catalyze360 in April 2025). Leadership was upgraded in 2025-2026 with co-founder Peyton Greenside moving from CSO to CEO and the appointment of Stefan Weigand (former Head of Large Molecule Research at Roche, overseeing roughly 350 scientists and 60-plus molecules into clinic) as Chief Scientific Officer, formalizing the company's transition from a platform/collaboration business to a clinical-stage biotech.

BigHat Biosciences firmographics

Firmographics
Name
BigHat Biosciences
Legal name
BigHat Biosciences, Inc.
Website
https://bighatbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
BigHat Biosciences is an AI/ML-guided antibody discovery and engineering company that uses a Milliner platform pairing cell-free synthetic biology with proprietary machine learning to design safer, more effective antibody therapeutics, partnering with leading biopharma (Lilly, J&J, AbbVie, Amgen, Merck) while advancing a wholly-owned pipeline of ADCs and T cell engagers toward the clinic in 2026.
Ownership category
akta.pro rank

BigHat Biosciences industry classification

Industry
Product category
AI-Driven Antibody Discovery & Engineering Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI antibody design
  • ML-guided biologics
  • Protein therapeutics platform
  • Synthetic biology discovery
  • Antibody engineering services

Where BigHat Biosciences is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BigHat Biosciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic biopharma collaborations: Multi-program discovery and engineering partnerships with leading biopharma (Eli Lilly, J&J, AbbVie, Amgen, Merck). These typically include upfront cash, R&D funding, success-based milestone payments, and downstream economics tied to development and commercialization.
  2. Equity investments from pharma partners: Strategic partners take equity stakes in BigHat alongside collaboration agreements (e.g., Eli Lilly equity investment under Lilly Catalyze360™ in April 2025). Equity capital supplements R&D funding and aligns partner incentives.
  3. Technology licensing (ADC platform inbound): Licenses inbound enabling technologies for internal programs — e.g., Synaffix (a Lonza company) GlycoConnect™, HydraSpace® and toxSYN® ADC technologies licensed for BigHat's next-gen ADC program, with associated development and manufacturing services from Lonza. BigHat retains full global rights to its programs.
  4. Data and platform service arrangements: BigHat contributes best-in-class ML expertise and high-quality Milliner-generated datasets to support external AI-enabled drug discovery platforms (e.g., Lilly TuneLab), enabling model benchmarking and foundation model training in exchange for collaboration value.

Pricing tiers

ModelBillingPrice
Other—Quote-based partnership pricing (not publicly disclosed)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

BigHat Biosciences product offering

Product offering

Core offering

BigHat Biosciences develops and operates the Milliner platform, a full-stack antibody discovery and engineering system that integrates a synthetic-biology-based high-speed wet lab (cell-free protein synthesis) with proprietary machine learning models in an iterative weekly design-build-test-learn cycle. The platform is commercialized through multi-program strategic collaborations with large biopharma (Eli Lilly, J&J, AbbVie, Amgen, Merck), supports BigHat's wholly-owned therapeutic pipeline (ADCs and T cell engagers in oncology and immunology), and is paired with technology licensing arrangements and platform service agreements.

Product overview

BigHat Biosciences operates a single integrated platform architecture rather than a portfolio of disconnected products. The core platform, Milliner, pairs a synthetic-biology-based high-throughput wet lab with machine-learning-guided design in a weekly design-build-test cycle. Sitting on top of Milliner is Reccy Antibody Design Studio (RADS), the AI orchestration layer that trains a weekly "zoo" of models and selects the best to design the next batch of antibodies, while Reccy itself (BigHat's custom LIMS++) acts as the data-control plane connecting instruments, robots, schedulers, and ML pipelines. These platform capabilities power BigHat's internal pipeline of wholly-owned therapeutics (BHB810 ADC for GI cancers, BHB299 and the avidity, AND-gated, and NOT-gated TCE programs in oncology and I&I), alongside partner programs with AbbVie, Johnson & Johnson, Amgen, Merck, Eli Lilly, and Lonza/Synaffix.

Differentiator

Problem solved

Functional benefit

Brands

  • Milliner: BigHat's AI/ML-powered, high-throughput, automated wet-lab antibody design and engineering platform; central data-generation engine that integrates synthetic biology with machine learning.
  • Reccy
  • Reccy Antibody Design Studio (RADS)

Products and services

  • Milliner Platform

Quantifiable outcome

  • Hundreds of recombinant antibodies synthesized, purified, and characterized in a single weekly workcell
  • +6 more outcomes

Companies that use BigHat Biosciences

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

BigHat Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature6 records

BigHat Biosciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship and core.

  • Eli Lilly (Lilly TuneLab)flagshipStrategic or Co-development Partner · 7 January 2026Collaboration to advance machine learning-enabled biologics discovery through Lilly TuneLab. BigHat will leverage its ML expertise and Milliner platform to rapidly generate diverse, high-quality datasets suitable for use in a generalizable antibody developability foundation model. Expands BigHat's existing relationship with Lilly.
  • Amazon Web Services (AWS)coreTechnology or Integration · 26 November 2025BigHat uses AWS to build digitally connected labs and is featured among customers in AWS's agentic AI life sciences portfolio announcement, alongside Bayer AG, Natera, Foundation Medicine, and Resilience. AWS previewed BigHat-related demonstrations at re:Invent 2025.
  • Johnson & Johnson (Janssen Biotech, Inc.)flagshipStrategic or Co-development Partner · 28 October 2025Strategic collaboration to leverage BigHat's integrated machine learning platform to design novel and challenging antibodies, successfully completed. Next stage advances multiple novel sequences targeting neuroscience therapeutic area.
  • Eli LillyflagshipStrategic or Co-development Partner · 17 April 2025Strategic collaboration to co-develop up to two antibody therapeutic programs using BigHat's Milliner platform. Lilly Catalyze360™ provides support while BigHat retains full global rights to its GI cancer ADC program. Includes equity investment from Lilly.
  • Synaffix (Lonza)coreOEM/ Whitelabel/ Licensing Partner · 30 October 2024Commercial license of Synaffix's late-clinical stage, site-specific ADC technology platform (GlycoConnect™, HydraSpace® and toxSYN® linker-payloads) for BigHat's next-gen ADC pipeline program. Through Lonza's umbrella, BigHat also gains access to end-to-end ADC development and manufacturing services (DNA-to-IND). The collaboration is critical for advancing BigHat's next-generation ADC program, currently at IND-enabling stage and on track to become BigHat's first clinical-stage program.
  • AbbVieflagshipStrategic or Co-development PartnerResearch collaboration to leverage AI/ML to discover next-generation therapeutic antibodies. AbbVie cites the collaboration as evidence of its commitment to integrate AI/ML-based approaches in drug discovery and development. Third-party reporting indicates $30M upfront and up to $325M+ in milestones.
  • AmgencoreStrategic or Co-development PartnerMulti-phase research collaboration; completion of first stage demonstrated Milliner's ability to quickly and significantly optimize next-generation single-domain antibodies, validating the platform against traditional technologies. Philip Tagari (former VP of Research at Amgen) provided quote endorsing the collaboration.
  • MerckcoreStrategic or Co-development PartnerResearch collaboration applying AI/ML across Merck's drug discovery capabilities. Merck's Juan Alvarez (VP of Discovery Biologics) cites the agreement as expanding their AI/ML strategy to enable molecular design of novel biologic candidates.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

BigHat Biosciences competitors and assessment

Company assessment

Direct peers

  • Generate Biomedicines: Flagship-backed AI-driven generative biology company developing de novo protein therapeutics, including antibodies, using foundation models and a wet-lab learning loop. Most direct competitor to BigHat's ML-guided antibody discovery and engineering model.
  • Insitro: ML-driven drug discovery company combining high-throughput biology, induced pluripotent stem cell-derived disease models, and ML to discover and develop therapeutics, including biologics. Overlaps with BigHat on the wet-lab-plus-ML platform thesis and biopharma partnership model.
  • AbCellera Biologics: Public antibody discovery company combining high-throughput single-cell screening with computational/ML approaches to discover and optimize antibody therapeutics, with a similar partnership-driven business model serving top biopharma.
  • Isomorphic Labs: Alphabet-backed drug discovery company spun out of DeepMind applying AlphaFold-derived AI to therapeutics design, including biologics. Direct competitor in the AI/ML-driven protein and antibody design space with substantially greater capital and compute resources.

Emerging players

  • Tessera Therapeutics: Flagship-backed gene writing company combining ML-driven protein engineering with synthetic biology. Shares BigHat's integration of ML and synthetic biology, though focused on genome engineering rather than antibody therapeutics.
  • Cradle Bio: Amsterdam-based AI company applying generative ML to protein engineering across modalities, with a partnership-led business model. Comparable in applying foundation models and ML to protein design, though its primary focus is broader than antibodies.
  • LabGenius: London-based AI-driven antibody discovery company using a closed-loop design-build-test-learn cycle to engineer next-generation antibody therapeutics. Closely mirrors BigHat's automation-plus-ML approach in the antibody niche, with a more recent funding history.
  • Adaptyv Bio: Early-stage protein engineering company using high-throughput wet-lab experimentation and ML to accelerate protein design. Smaller and earlier-stage than BigHat, but operates in a similar ML-guided biologics design space.

Broad incumbents

  • Recursion Pharmaceuticals: Public techbio company combining high-throughput automated wet-lab experimentation with ML at scale, focused on small molecule and target identification. Adjacent platform model with overlap in ML-guided biology and biopharma partnerships, though concentrated in small molecules rather than antibodies.
  • Ginkgo Bioworks: Public synthetic biology platform company combining automated high-throughput biology with ML for cell engineering and protein production. Overlaps with BigHat on the synthetic-biology-plus-ML platform concept, though Ginkgo's primary focus is organism engineering and biomanufacturing rather than antibody therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BigHat Biosciences social profiles

Digital presence

BigHat Biosciences compliance and trust

Trust signal

Compliance1 record

BigHat Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BigHat Biosciences leadership team

Management profile

Number of profiles

Profiles10 records

BigHat Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BigHat Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BigHat Biosciences

What does BigHat Biosciences do?

BigHat Biosciences develops and operates the Milliner platform, a full-stack antibody discovery and engineering system that integrates a synthetic-biology-based high-speed wet lab (cell-free protein synthesis) with proprietary machine learning models in an iterative weekly design-build-test-learn cycle. The platform is commercialized through multi-program strategic collaborations with large biopharma (Eli Lilly, J&J, AbbVie, Amgen, Merck), supports BigHat's wholly-owned therapeutic pipeline (ADCs and T cell engagers in oncology and immunology), and is paired with technology licensing arrangements and platform service agreements.

Is BigHat Biosciences a public or private company?

BigHat Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was BigHat Biosciences founded?

BigHat Biosciences was founded in 2019. It employs 51 to 100 people.

Where is BigHat Biosciences based?

BigHat Biosciences is headquartered in San Mateo, United States, in the North America region.

How does BigHat Biosciences make money?

Four revenue lines are on record. Strategic biopharma collaborations are the primary driver. The others are equity investments from pharma partners, technology licensing (ADC platform inbound) and data and platform service arrangements.

Who are BigHat Biosciences's main competitors?

Direct peers on record are Generate Biomedicines, Insitro, AbCellera Biologics and Isomorphic Labs. Emerging players are Tessera Therapeutics, Cradle Bio, LabGenius and Adaptyv Bio. Broad incumbents are Recursion Pharmaceuticals and Ginkgo Bioworks.

Does BigHat Biosciences have an API?

No public API is recorded for BigHat Biosciences.

What industry is BigHat Biosciences in?

BigHat Biosciences's product category is AI-Driven Antibody Discovery & Engineering Platform. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AlleyWatchThe Weekly Notable Startup Funding Report: 9/28/26A weekly funding report for the week ending 9/26/26 covers nineteen deals, including Baselayer, BigHat Biosciences, and Cyera, totaling $2.5B in new funding. Notable rounds include Baselayer's $35M, BigHat's $75M, and Cyera's $400M, with backers such as Afore Capital, 8VC, and Goldman Sachs Growth Equity.AI InsiderBigHat Biosciences Closes $75M Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein DesignBigHat Biosciences closed a $75 million Series C co-led by DFJ Growth and Premji Invest, bringing total funding to $223 million. The company will use the funds to advance its AI-designed therapeutics, including BHB810, which dosed the first patient in a Phase 1 trial, and BHB299, planned for human trials in 2027.citybizBigHat Biosciences Raises $75M Series C to Advance AI-Designed Cancer DrugsBigHat Biosciences raised $75 million in a Series C round co-led by DFJ Growth and Premji Invest, bringing total funding to $223 million. The company will use the capital to expand its AI protein-design platform and advance two oncology programs, including BHB810, which entered Phase 1 trials. Its second candidate, BHB299, is expected to enter human trials in 2027.Analytics InsightWeekly Startup Funding Roundup: AI Infrastructure, Biotech, Enterprise Tech Attract Big InvestmentsFive AI-related startups raised funding this week, including PicoJool's $27.5M Series A, BigHat Biosciences' $75M Series C, and Ema's $77M Series B. The rounds span optical hardware, biotech, procurement software, and retail automation, showing capital moving beyond model development into infrastructure and applications.The Pharma LetterBigHat BiosciencesBigHat Biosciences closed a $75 million Series C in September 2026, bringing total funding to $223 million. Its lead asset, BHB810, a CDH17-directed antibody-drug conjugate, has dosed its first patient in a Phase I/II study for gastrointestinal cancers. The company plans to use the funds for clinical development of BHB810 and BHB299.Pulse 2.0BigHat Biosciences Raises $75 Million Series C Co-Led By DFJ Growth And Premji InvestBigHat Biosciences raised $75 million in a Series C co-led by DFJ Growth and Premji Invest, bringing total funding to $223 million. The company will use the funds to advance its clinical-stage drug pipeline, including BHB810, which has dosed its first Phase 1 patient. The financing also supports scaling its AI-driven protein design platform.BioSpaceBigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein DesignBigHat Biosciences closed a $75 million Series C financing co-led by DFJ Growth and Premji Invest, bringing total funding to $223 million. The proceeds will support its AI-designed therapeutics pipeline, including BHB810 and BHB299, and its platform for rapid protein design.The Pharma LetterBigHat Biosciences closes $75 million Series C financingBigHat Biosciences closed a $75 million Series C financing, bringing total funding to $223 million. The round was co-led by DFJ Growth and Premji Invest, with participation from Catalio Capital, LG Technology Ventures, and existing investors including Amgen, Eli Lilly, and Merck.Business Wire BlogBigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein DesignBigHat Biosciences closed a $75 million Series C financing co-led by DFJ Growth and Premji Invest, bringing total funding to $223 million. The proceeds will advance its clinical-stage AI-designed therapeutics, including BHB810, and its platform for rapid protein design. The company plans to begin human trials of BHB299 in 2027.FinancialContent Business PageBigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein DesignBigHat Biosciences closed a $75 million Series C financing co-led by DFJ Growth and Premji Invest, bringing total funding to $223 million. The proceeds will support its AI-designed therapeutics pipeline, including BHB810 and BHB299, and its platform for rapid protein design.